Abstract Procalcitonin (PCT), a 116-aminoacids prohormone, has been substantially studied over the last 2 decades in the field of sepsis. Disappointingly low sensitivity values led to the abandonment of the concept of it as a diagnostic tool and then to its being considered more as a prognostic marker with a good correlation with severe infection. Later on, growing concerns about multidrug-resistant bacteria in the ICU environment and about the cost and side effects of antibiotics suggested that PCT might prove to be a valuable asset in stewardship programs. Numerous but hardly comparable randomized controlled trials assessing either initiation or deescalation in ICU patients have been published. Stewardship encompassing PCT should focus on the latter, because of the high negative predictive value of this biomarker. However, there still would be safety concerns if a systematic implementation of PCT were to be considered in daily stewardship programs in the ICU, especially in extrathoracic sepsis.
Introduction
Since its first description in children and burned patients 2 decades ago [1] , procalcitonin (PCT) has traveled a long way from diagnosis of infectious chronic obstructive pulmonary disease (COPD) exacerbation in the emergency department to its current concept as a possible tool for antibiotic stewardship in our busier intensive care units (ICUs) with worsening ecological environments [2, 3] (Fig. 1) . Indeed, it was first thought to be helpful in the discrimination between severe infection and nonspecific hyperinflammatory states [4•] . Intensive care physicians are daily challenged with the risk of initiating useless and potentially toxic (for the patient and the environment) treatments in the absence of specific clinical signs and of a gold-standard biomarker in the field of sepsis. PCT was historically studied in various settings and clinical conditions, including emergency departments, neonatal sepsis, and ICU patients [5, 6] . However, unacceptably low sensitivity values in the setting of critically ill patients, ranging from 67 % to 80 % depending on the chosen cutoff [7, 8, 9 •, 10•], led to its being considered rather as a prognostic tool in terms of severity of illness and outcome. In that sense, PCT met the fate of other acute phase reactants that did not show satisfactory specificity. PCT is notoriously raised, in the absence of infection, in pancreatitis, ischemic bowel disease, cardiopulmonary bypass, and metastatic disease [11] and with the intake of some drugs (monoclonal antibodies, antithymocyte globulin, etc.) [12••, 13] . PCT does not rise incases of local bacterial, viral, parasitic, or fungal infection. Between 2006 and 2008, numerous studies involving very different types of patients (medical vs. surgical, immunocompetent vs. immunocompromised) and indications (severe community-acquired pneumonia, sepsis) [14, 15] were undertaken. Some studies focused strictly on prognostic significance, whereas others combined the diagnostic and prognostic abilities of the test. Interestingly, PCT was combined with others biomarkers (CRP, sTREM-1, SUPAR, TNF-alpha, IL-6, IL-8), clinical scoring systems (SAPSII), and biological markers of sepsis such as lactate [16] [17] [18] . The results were better in the multimodal approach, as opposed to the use of PCT alone, for determination of outcome (AUC 0.72-0.88). It is now commonly admitted that higher values (1.5-over 5 μg/l) in high-risk patients are correlated with bacterial load and bacteremia [19] , severity of organ failure [20, 21] , and, in some studies, mortality [6, 22] .
Core Text
After an initial encouraging report on the usefulness of PCT for safe reduction of antibiotic therapy in lower respiratory tract infections (RTIs) in 2004 [23, 24] , it was not until 2008 that the concept of PCT as a possible antibiotic stewardship tool emerged in clinical studies involving ICU patients [25••] ( Table 1 ). The growing pressure of multidrug-resistant bacteria in the ICU environment, combined with considerations regarding cost and limitation of drug toxicity and interactions [26, 27] , offered the perfect opportunity for a new appraisal of this biomarker, which had somehow failed to fulfill its promises. It is considered to be useful because of favorable kinetics [28] and a high negative predictive value [17, [29] [30] [31] .
Antibiotic stewardship encompassing PCT can be regarded as a lack of initiation of antibiotics in the absence of bacterial infection, thus calling into question the sensitivity of the biomarker, versus rapid stopping of them, in cases of a decrease of PCT, on the basis of a daily check, either because clinical cure is achieved or because infection has been safely ruled out. Now, the first strategy encounters two hurdles. First, it obviously does not fit into clinical practice dealing with seriously ill patients, since protocol-overruling reports range from 20 % to 65 % [30, 32•, 33, 34] . In the Layios study, in 43/80 patients (belonging to the PCT arm, which comprised 258 patients) who had a PCT <0.25 μg/l, the diagnosis was overruled by the treating physician, and they received antibiotics. Of note, 69.8 % of these treatments (30/43) were a posteriori confirmed by the infectious diseases specialist to have been appropriately initiated. Second, poor diagnostic sensitivity was once again confirmed recently (AUC 0.69), and two recent studies showed that the strategy is a failure in an escalating or initiation process [10•, 30] .
The second strategy, however, is supported by the physiological decline within 48 h in noninfected patients [35, 36] and has recently been shown to be cost effective, thanks to a 2-day decrease in antibiotic consumption, although not altogether convincingly safe [32•, 37] . The same degree of concern about a possible excess of mortality had been raised in the PRORATA study [33] , and the debate is ongoing. Prior to 2010, five randomized controlled trials (RCTs) evaluating deescalation in critically ill patients had shown reduction in antibiotic consumption, without excess of morbidity or mortality [38] . Interestingly, the same authors put into perspective the fact that in nondocumented sepsis, the optimal duration of antibacterial therapy is not known. Several other studies have been published since then, reporting the same proportion of safe antibiotic-free days (2-4 days) [31, 39•, 40] , but only two focused merely on severe extra-thoracic sepsis. The ESICM meta-analysis reviewed seven RCTs in critically ill patients and confirmed the safety of shortening antibiotic administration by just over 3 days, in terms of a similar rate of superinfections and recurrence of infection in the PCT-guided arm. A consistent reduction of antibiotic therapy was also reported in the review published by Schuetz et al. [41••] , mainly owing to shorter courses of antibiotic therapy (and not withholding of initiation) among moderate-and high-acuity care patients. The Schuetz study mixed lower RTIs and severe sepsis and septic shock without further definition. The proposed PCT cutoff values in the deescalating strategy in the ICU were roughly the same throughout all the recently published trials and metaanalyses, meaning a drop of 80 %-90 % from the peak value or a return to a level less than 0.25-1 μg/l in patients showing clinical signs of recovery. Mortality has not been significantly affected by that strategy in any of the trials published so far. Importantly, PCT was extensively studied in the setting of lower RTIs namely, ventilator-acquired pneumonia (VAP) in immunocompetent adults-while severe sepsis (i.e., a syndrome defined as the host's systemic inflammatory response syndrome [SIRS] to infection) was the second cause of inclusion of patients. However, the source and/or the microbiological proof of infection have seldom been reported. This is very intriguing after almost 2 decades of striving-and with, sometimes, rigorous research-to establish the utility of a biomarker in less rigorous conditions. It is also, in our view, the biggest difficulty to overcome, since modern intensive care is becoming, alas, more and more syndromic. Of interest, the recently published and prematurely stopped study of Annane et al. [42] failed to include patients because 80.6 % of the eligible patients had a documented source of infection within 48 h of recognition of SIRS (before randomization), 77.6 % of whom had a documented pathogen. Now this was considered to be a major design flaw, but one definitely has to put into perspective the utility of a biomarker when modern pathogen identification techniques and experienced clinical judgment are combined. This point is very interestingly raised by Póvoa et al. [43] , who reminded us of two studies, going 10 years back, that had shown the effectiveness of a shorter (6-8 days) duration of antibiotic therapy to be equal to that of a long-term course (10-21 days) in VAP, but without the use of any biomarker. Hence, the decision to recommend PCT's usage in the recent guidelines for deescalation in lower RTIs even in the case of septic shock [44] , recommending caution regarding their implementation in immunocompromised and unstable patients. This is in line with most studies focusing on the need for supplementary data in favor of safe antibiotic stewardship, always encompassing PCT in a multimodal approach. A prospective upcoming and well-enrolled study (the SAPS study), the largest to be conducted so far in ICU patients, will perhaps be able to answer questions about the cost, safety, and effectiveness of such a strategy [45] . However, although convincing from the physiopathological and, sometimes, evidence-based point of view, PCT's systematical implementation as a prognostic tool or, for therapeutic monitoring, as a clinical algorithm for ICU patients has not been widely encouraged so far.
Conclusion
PCT as an antibiotic stewardship tool aiming at appropriately initiating antibiotics-that is, only in the setting of severe infection-has recently once again proven to be futile, if not detrimental. The 2013 surviving sepsis campaign (SSC) guidelines propose PCT as a diagnostic aid, in conjunction with the usual clinical signs, provided its value is superior to 2 standard deviations above the normal value. This is, in our opinion, a surrogate marker for poor sensitivity, and it would have been more prudent not to include it at all in the diagnostic strategy. Now, interest in PCT's ability to contribute to infected critically ill patients' diagnosis and prognosis has not worn out, as large-scale ongoing clinical studies attest (accessed on clinicaltrials.gov on May 13, 2013), but we are doubtful about their ultimate daily clinical implementation, given the amount of literature already available and the understandable reluctance of the intensive care physician, facing the possibility of uncontrolled sepsis, not to initiate antibiotics.
Hence, PCT as a therapeutic monitoring tool has looked like an attractive alternative in view of its high negative predictive value, but conclusive data concerning safety of this strategy are still lacking, at least in extra-thoracic severe sepsis. Concerning VAP, past studies have shown efficacious and safe shorter duration of antibiotic therapy without the need for a biomarker. Low adherence to protocol, even in the setting of controlled infection, is another hurdle to its implementation in daily clinical practice, since reports of overruling range from 16 % to 65 % [32•, 43 ]. Only a grade 2C level of recommendation was attributed to PCT in the recently updated SSC guidelines when deescalation was considered. Rather, narrowing of the spectrum of antibiotics or stopping is left to "clinical judgment and information."
On the other hand, high-throughput molecular techniques such as multiplexed PCR and mass spectrometry allow more rapid and less empiric pathogen identification nowadays [46] . These techniques should be evaluated in terms of cost effectiveness, sensitivity, and specificity as part of a multimodal stewardship program in the ICU that could encompass bioscores such as the one recently described by Gibot et al. [47•] . This approach would thus imply a patient-tailored treatment based on individual phenotypic characteristics, combined with a biomarker allowing prompt stopping of antibiotics in the absence of infection or, even better, consensus on the optimal duration of therapy in sepsis without bacterial documentation.
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